Skip to main content
Top
Published in: BMC Nephrology 1/2015

Open Access 01-12-2015 | Research article

Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients

Authors: Da Shang, Qionghong Xie, Xiaolin Ge, Huanqing Yan, Jing Tian, Dingwei Kuang, Chuan-Ming Hao, Tongying Zhu

Published in: BMC Nephrology | Issue 1/2015

Login to get access

Abstract

Background

Coronary artery calcification (CAC) is associated with cardiovascular mortality in end-stage renal disease (ESRD) patients. The present study aimed to identify modifiable risk factors for CAC progression in peritoneal dialysis (PD) patients.

Methods

Adult patients who received regular PD for more than 6 months and underwent a series of coronary artery calcification score (CaCS) measurements by multislice spiral computed tomography (MSCT) with an interval of ≥ 6 months were included in this observational cohort study. The demographic characteristics and clinical data, including laboratory data and adequacy of PD, were collected. Curve estimation was used to fit the straight line and obtain the slope. Binary logistic regression was performed to identify the independent risk factors for CAC progression in the PD patients, and multivariate linear regression was conducted to identify factors associated with hyperphosphatemia.

Results

A total of 207 adult patients on PD (116 men, 56.0 %) with a mean age of 59.8 ± 15.9 years were recruited to this study, and 157 of them (75.8 %) received three or more CaCS assessments. The patients were divided into a slow group (n = 137) and a rapid group (n = 70) according to the linear regression slope or the average speed of development. The follow-up time was 33.0 ± 18.8 months. Multivariate logistic regression revealed that age and serum phosphate level were independent risk factors for CAC progression after adjustments. Multivariate linear regression revealed that hyperphosphatemia was associated with elevations in the transferrin and serum albumin levels and normalized protein catabolic rate (nPCR) and reductions in the hemoglobin level, residual Ccr, and PD Ccr.

Conclusions

Hyperphosphatemia is an independent risk factor for CAC progression, and the serum phosphate level may be associated with protein intake and PD adequacy. These results provide important information for the clinical management of ESRD patients.
Literature
1.
go back to reference Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–9.CrossRefPubMed Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S112–9.CrossRefPubMed
2.
go back to reference Go AS, Chertow GM, Fan D, McCulloch CE, Hau CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305. Go AS, Chertow GM, Fan D, McCulloch CE, Hau CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–305.
3.
go back to reference Elias-Smale SE, Proenca RV, Koller MT, Kavousi M, van Rooij FJ, Hunink MG, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56(17):1407–14. Elias-Smale SE, Proenca RV, Koller MT, Kavousi M, van Rooij FJ, Hunink MG, et al. Coronary calcium score improves classification of coronary heart disease risk in the elderly: the Rotterdam study. J Am Coll Cardiol. 2010;56(17):1407–14.
4.
go back to reference Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010;6(8):451–60.CrossRefPubMed Krediet RT, Balafa O. Cardiovascular risk in the peritoneal dialysis patient. Nat Rev Nephrol. 2010;6(8):451–60.CrossRefPubMed
5.
go back to reference Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–42. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38(4):938–42.
6.
go back to reference Shimoyama Y, Tsuruta Y, Niwa T. Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients. Journal Of Renal Nutrition. 2012;22(1):139–42.CrossRefPubMed Shimoyama Y, Tsuruta Y, Niwa T. Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients. Journal Of Renal Nutrition. 2012;22(1):139–42.CrossRefPubMed
7.
go back to reference Shantouf RS, Budoff MJ, Ahmadi N, Ghaffari A, Flores F, Gopal A, et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. American Journal Of Nephrology. 2010;31(5):419–25. Shantouf RS, Budoff MJ, Ahmadi N, Ghaffari A, Flores F, Gopal A, et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. American Journal Of Nephrology. 2010;31(5):419–25.
8.
go back to reference Ohtake T, Ishioka K, Honda K, Oka M, Maesato K, Mano T, et al. Impact of coronary artery calcification in hemodialysis patients: Risk factors and associations with prognosis. Hemodialysis International. 2010;14(2):218–25. Ohtake T, Ishioka K, Honda K, Oka M, Maesato K, Mano T, et al. Impact of coronary artery calcification in hemodialysis patients: Risk factors and associations with prognosis. Hemodialysis International. 2010;14(2):218–25.
9.
go back to reference Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrology Dialysis Transplantation. 2003;18(6):1152–8. Moe SM, O'Neill KD, Fineberg N, Persohn S, Ahmed S, Garrett P, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrology Dialysis Transplantation. 2003;18(6):1152–8.
10.
go back to reference Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Santos RD, Miname M, et al. The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int. 2007;27(3):340–6. Ammirati AL, Dalboni MA, Cendoroglo M, Draibe SA, Santos RD, Miname M, et al. The progression and impact of vascular calcification in peritoneal dialysis patients. Perit Dial Int. 2007;27(3):340–6.
11.
go back to reference Kim HG, Song SW, Kim TY, Kim YO. Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis. Hemodialysis International. 2011;15(4):460–7. Kim HG, Song SW, Kim TY, Kim YO. Risk factors for progression of aortic arch calcification in patients on maintenance hemodialysis and peritoneal dialysis. Hemodialysis International. 2011;15(4):460–7.
12.
go back to reference Tamashiro M, Iseki K, Sunagewa O, Inoue T, Higa S, Afuso H, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. American Journal Of Kidney Diseases. 2001;38(1):64–9. Tamashiro M, Iseki K, Sunagewa O, Inoue T, Higa S, Afuso H, et al. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. American Journal Of Kidney Diseases. 2001;38(1):64–9.
13.
go back to reference Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21(7):1915–20.CrossRefPubMed Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21(7):1915–20.CrossRefPubMed
14.
go back to reference Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrology Dialysis Transplantation. 2011;26(5):1662–9. Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrology Dialysis Transplantation. 2011;26(5):1662–9.
15.
go back to reference Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13(5):551–61. Locatelli F, Del Vecchio L, Violo L, Pontoriero G. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles. Expert Opin Drug Saf. 2014;13(5):551–61.
16.
go back to reference Dusilova Sulkova S. Bone disease in chronic renal failure and its modern therapy. Vnitr Lek. 2011;57(7–8):620–5.PubMed Dusilova Sulkova S. Bone disease in chronic renal failure and its modern therapy. Vnitr Lek. 2011;57(7–8):620–5.PubMed
17.
18.
go back to reference Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18.
19.
go back to reference Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948–55. Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011;26(6):1948–55.
20.
go back to reference Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–80. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–80.
21.
go back to reference Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388–96. Isakova T, Gutierrez OM, Chang Y, Shah A, Tamez H, Smith K. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388–96.
22.
go back to reference Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003;14(9 Suppl 4):S300–4.CrossRefPubMed Giachelli CM. Vascular calcification: in vitro evidence for the role of inorganic phosphate. J Am Soc Nephrol. 2003;14(9 Suppl 4):S300–4.CrossRefPubMed
23.
go back to reference Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15(11):2857–67.
24.
go back to reference Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol. 2007;18(11):2996–3003. Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S, Milford D. Mineral metabolism and vascular damage in children on dialysis. J Am Soc Nephrol. 2007;18(11):2996–3003.
25.
go back to reference Stompor TP, Pasowicz M, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. American Journal Of Kidney Diseases. 2004;44(3):517–28. Stompor TP, Pasowicz M, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K. Trends and dynamics of changes in calcification score over the 1-year observation period in patients on peritoneal dialysis. American Journal Of Kidney Diseases. 2004;44(3):517–28.
26.
go back to reference Chertow GM, Burke SK, Raqqi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;70:245–52. Chertow GM, Burke SK, Raqqi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;70:245–52.
27.
go back to reference Sakata N, Takeuchi K, Noda K, Saku K, Tachikawa Y, Tashiro T. Calcification of the medial layer of the internal thoracic artery in diabetic patients: Relevance of glycoxidation. Journal Of Vascular Research. 2003;40(6):567–74. Sakata N, Takeuchi K, Noda K, Saku K, Tachikawa Y, Tashiro T. Calcification of the medial layer of the internal thoracic artery in diabetic patients: Relevance of glycoxidation. Journal Of Vascular Research. 2003;40(6):567–74.
28.
go back to reference Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis. 2004;43(4):712–20. Wang AY, Woo J, Sea MM, Law MC, Lui SF, Li PK. Hyperphosphatemia in Chinese peritoneal dialysis patients with and without residual kidney function: what are the implications? Am J Kidney Dis. 2004;43(4):712–20.
29.
go back to reference Rroji M, Seferi S, Cafka M, Petrela E, Likaj E, Barbullushi M. Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients? Int Urol Nephrol. 2014;46(1):175–82. Rroji M, Seferi S, Cafka M, Petrela E, Likaj E, Barbullushi M. Is residual renal function and better phosphate control in peritoneal dialysis an answer for the lower prevalence of valve calcification compared to hemodialysis patients? Int Urol Nephrol. 2014;46(1):175–82.
30.
go back to reference Civilibal M, Caliskan S, Kurugoglu S, Candan C, Canpolat N, Sever L. Progression of coronary calcification in pediatric chronic kidney disease stage 5. Pediatric Nephrology. 2009;24(3):555–63. Civilibal M, Caliskan S, Kurugoglu S, Candan C, Canpolat N, Sever L. Progression of coronary calcification in pediatric chronic kidney disease stage 5. Pediatric Nephrology. 2009;24(3):555–63.
31.
go back to reference Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108(4):c278–83. Takei T, Otsubo S, Uchida K, Matsugami K, Mimuro T, Kabaya T. Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. Nephron Clin Pract. 2008;108(4):c278–83.
32.
go back to reference Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–7. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87(7):E10–7.
33.
go back to reference Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP. Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl. 2008;108:S152–8. Yavuz A, Ersoy FF, Passadakis PS, Tam P, Evaggelos DM, Katopodis KP. Phosphorus control in peritoneal dialysis patients. Kidney Int Suppl. 2008;108:S152–8.
34.
go back to reference Kovesdy CP, Mucsi I, Czira ME, Rudas A, Ujszaszi A, Rosivall L. Association of serum phosphorus level with anemia in kidney transplant recipients. Transplantation. 2011;91(8):875–82. Kovesdy CP, Mucsi I, Czira ME, Rudas A, Ujszaszi A, Rosivall L. Association of serum phosphorus level with anemia in kidney transplant recipients. Transplantation. 2011;91(8):875–82.
35.
go back to reference Yoshida K, Yoneda T, Kimura S, Fujimoto K, Okajima E, Hirao Y. Polyamines as an inhibitor on erythropoiesis of hemodialysis patients by in vitro bioassay using the fetal mouse liver assay. Therapeutic Apheresis Dialysis. 2006;10(3):267–72. Yoshida K, Yoneda T, Kimura S, Fujimoto K, Okajima E, Hirao Y. Polyamines as an inhibitor on erythropoiesis of hemodialysis patients by in vitro bioassay using the fetal mouse liver assay. Therapeutic Apheresis Dialysis. 2006;10(3):267–72.
Metadata
Title
Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients
Authors
Da Shang
Qionghong Xie
Xiaolin Ge
Huanqing Yan
Jing Tian
Dingwei Kuang
Chuan-Ming Hao
Tongying Zhu
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2015
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-015-0103-8

Other articles of this Issue 1/2015

BMC Nephrology 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.